<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>NAFLD Primary Care Algorithm – Quick Reference</title>
  <meta name="description" content="One‑page primary care algorithm for NAFLD: suspicion, assessment, fibrosis risk, management, referral and follow‑up." />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&family=Source+Serif+4:ital@0;1&display=swap" rel="stylesheet">
  <style>
    :root {
      /* Calm, light palette (no dark mode) */
      --bg: #f7fafc;
      --panel: #ffffff;
      --ink: #1f2937;           /* soft slate */
      --muted: #6b7280;
      --primary: #0ea5e9;       /* sky */
      --primary-600: #0284c7;
      --accent: #22c55e;        /* green */
      --warning: #f59e0b;       /* amber */
      --danger: #ef4444;        /* red */
      --line: #e5e7eb;          /* light gray */
      --chip: #e0f2fe;          /* light sky */
      --shadow: 0 8px 16px rgba(2, 132, 199, 0.08), 0 2px 8px rgba(31, 41, 55, 0.06);
      --radius: 16px;
    }

    html, body { height: 100%; }
    body {
      margin: 0;
      font-family: Inter, system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji", "Segoe UI Emoji";
      color: var(--ink);
      background: linear-gradient(180deg, #f9fbfd 0%, var(--bg) 100%);
    }

    .wrap {
      max-width: 1100px;
      margin: 24px auto 48px auto;
      padding: 0 20px;
    }

    /* ----- Header ----- */
    header.hero {
      background: radial-gradient(1600px 600px at 10% -20%, #e0f2fe 0%, transparent 50%),
                  radial-gradient(1200px 500px at 90% -10%, #fde68a50 0%, transparent 60%),
                  var(--panel);
      border: 1px solid var(--line);
      box-shadow: var(--shadow);
      border-radius: var(--radius);
      padding: 28px 28px 22px 28px;
      position: relative;
      overflow: hidden;
    }

    .hero h1 {
      margin: 0 0 6px 0;
      font-size: clamp(26px, 3vw, 36px);
      letter-spacing: -0.02em;
    }

    .kicker { 
      display: inline-flex; align-items: center; gap: 10px; 
      font-weight: 600; font-size: 13px; text-transform: uppercase; letter-spacing: .12em; color: var(--primary-600);
      margin-bottom: 10px;
    }
    .kicker svg { height: 18px; width: 18px; }

    .meta { color: var(--muted); font-size: 14px; }
    .badge {
      display: inline-flex; align-items: center; gap: 8px;
      background: var(--chip);
      border: 1px solid #bae6fd;
      color: #075985;
      padding: 6px 10px; border-radius: 999px; font-size: 12.5px; font-weight: 600; margin-right: 8px;
    }

    /* ----- Layout ----- */
    .grid {
      display: grid;
      grid-template-columns: 1.1fr 0.9fr; /* main | sidebar */
      gap: 22px;
      margin-top: 22px;
    }

    @media (max-width: 960px) {
      .grid { grid-template-columns: 1fr; }
      .sidebar { order: -1; }
    }

    .card {
      background: var(--panel);
      border: 1px solid var(--line);
      border-radius: var(--radius);
      box-shadow: var(--shadow);
      padding: 20px 20px 16px 20px;
    }

    .card h2 { font-size: 20px; margin: 6px 0 14px; letter-spacing: -0.01em; }
    .card h3 { font-size: 16px; margin: 18px 0 6px; color: var(--primary-600); }

    .list {
      margin: 0; padding: 0 0 0 20px; line-height: 1.55;
    }
    .list li { margin: 6px 0; }
    .hint { color: var(--muted); font-size: 13.5px; }

    /* ----- Flow Chips / Steps ----- */
    .steps { display: grid; gap: 14px; }
    .step {
      background: linear-gradient(180deg, #ffffff, #fbfdff);
      border: 1px solid var(--line);
      padding: 14px 14px 12px; border-radius: 14px; position: relative;
    }
    .step .title { font-weight: 700; font-size: 14.5px; display: flex; align-items: center; gap: 10px; }
    .step .title .num {
      height: 28px; width: 28px; border-radius: 50%; display: grid; place-items: center; font-weight: 800; font-size: 13px;
      background: #e0f2fe; color: #075985; border: 1px solid #bae6fd;
    }
    .step .body { margin-top: 8px; font-size: 14.5px; }

    /* ----- Table for thresholds ----- */
    table { width: 100%; border-collapse: collapse; font-size: 14.5px; }
    th, td { padding: 10px 12px; border-bottom: 1px solid var(--line); text-align: left; }
    th { background: #f1f5f9; font-weight: 700; }
    tr:last-child td { border-bottom: 0; }

    .tags { display: flex; flex-wrap: wrap; gap: 8px; margin-top: 8px; }
    .tag { background: #f0f9ff; border: 1px solid #e0f2fe; color: #075985; padding: 4px 10px; border-radius: 999px; font-size: 12.5px; font-weight: 600; }

    .callout { 
      background: linear-gradient(180deg, #f0fdf4, #ffffff 40%);
      border: 1.5px solid #bbf7d0; padding: 14px 14px; border-radius: 14px; 
    }
    .callout strong { color: #14532d; }

    .alert { 
      background: linear-gradient(180deg, #fff7ed, #ffffff 40%);
      border: 1.5px solid #fed7aa; padding: 14px 14px; border-radius: 14px;
    }

    .divider { height: 1px; background: var(--line); margin: 14px 0; }

    /* ----- Sticky mini-TOC ----- */
    .sidebar { position: sticky; top: 16px; align-self: start; }
    .toc { list-style: none; margin: 0; padding: 0; }
    .toc li { margin: 8px 0; }
    .toc a { text-decoration: none; color: var(--ink); font-size: 14.5px; }
    .toc a:hover { color: var(--primary-600); }

    /* ----- Print styling: keep to one A4 page if possible ----- */
    @media print {
      :root { --shadow: none; }
      body { background: #fff; }
      header.hero { box-shadow: none; }
      .grid { grid-template-columns: 1fr 0.7fr; gap: 16px; }
      .card { box-shadow: none; }
      a[href]:after { content: ""; } /* remove URL printing */
    }

    /* Reduce motion accessibility */
    @media (prefers-reduced-motion: reduce) {
      * { transition: none !important; animation: none !important; }
    }
  </style>
</head>
<body>
  <div class="wrap" role="document">
    <header class="hero" aria-label="NAFLD quick reference header">
      <div class="kicker" aria-hidden="true">
        <!-- medical icon -->
        <svg viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true"><path d="M6 12h12M12 6v12" stroke="#0284c7" stroke-width="2.2" stroke-linecap="round"/></svg>
        Quick Reference Algorithm
      </div>
      <h1>NAFLD in Primary Care</h1>
      <p class="meta">Age ≥16 years • Focused on rapid decision‑making in consultations • Last reviewed Oct 2023</p>
      <div style="margin-top:12px">
        <span class="badge" title="Main aim">Reduce disease progression</span>
        <span class="badge" title="Main aim">Lower cardio‑metabolic risk</span>
        <span class="badge" title="Care setting">Primary care first</span>
      </div>
    </header>

    <main class="grid" aria-label="content grid">
      <!-- Main Column -->
      <section class="card" id="suspect" aria-labelledby="suspect-h2">
        <h2 id="suspect-h2">1) When to Suspect NAFLD</h2>
        <ul class="list">
          <li>Incidental <strong>raised ALT</strong> (typically ≤3× ULN, > AST) persisting &gt;3 months.</li>
          <li>Risk factors: <strong>obesity</strong>, <strong>T2DM</strong>, dyslipidaemia, hypertension, metabolic syndrome.</li>
          <li>Ultrasound with <em>increased hepatic echogenicity</em> (fatty liver).</li>
          <li>Exclude excess alcohol and secondary causes (viral hepatitis, autoimmune, haemochromatosis, Wilson’s, α1‑antitrypsin deficiency).</li>
        </ul>
        <p class="hint">Ultrasound is sensitive for moderate–severe steatosis; normal LFTs/US do <em>not</em> exclude NAFLD.</p>
      </section>

      <aside class="card sidebar" aria-label="table of contents">
        <h2 style="margin-bottom:8px">On this page</h2>
        <ul class="toc" role="navigation">
          <li><a href="#suspect">Suspect NAFLD</a></li>
          <li><a href="#assess">Initial Assessment</a></li>
          <li><a href="#fibrosis">Assess Fibrosis</a></li>
          <li><a href="#manage">Primary Care Management</a></li>
          <li><a href="#refer">When to Refer</a></li>
          <li><a href="#specialist">Specialist Actions</a></li>
          <li><a href="#followup">Follow‑Up</a></li>
        </ul>
      </aside>

      <section class="card" id="assess" aria-labelledby="assess-h2">
        <h2 id="assess-h2">2) Initial Assessment</h2>
        <div class="steps">
          <div class="step">
            <div class="title"><span class="num">A</span> History</div>
            <div class="body">Symptoms (fatigue/RUQ pain), alcohol intake (<strong>&lt;20g/day women</strong>, <strong>&lt;30g/day men</strong>), comorbidities, drugs.</div>
          </div>
          <div class="step">
            <div class="title"><span class="num">B</span> Examination</div>
            <div class="body">BMI, waist circumference, BP, and signs of advanced liver disease (jaundice, spider naevi, palmar erythema, ascites, hepatosplenomegaly, encephalopathy).</div>
          </div>
          <div class="step">
            <div class="title"><span class="num">C</span> Investigations</div>
            <div class="body">
              LFTs, FBC (platelets), clotting; hepatitis B/C; autoantibodies; ferritin ± transferrin saturation; caeruloplasmin (&lt;40y); α1‑antitrypsin (if indicated); HbA1c; lipids; U&amp;E; TFTs; coeliac serology.
            </div>
          </div>
        </div>
      </section>

      <section class="card" id="fibrosis" aria-labelledby="fibrosis-h2">
        <h2 id="fibrosis-h2">3) Assess Risk of Advanced Fibrosis</h2>
        <p>Use non‑invasive tools first. Scores suggesting advanced fibrosis:</p>
        <table aria-label="fibrosis thresholds">
          <thead>
            <tr><th>Tool</th><th>Variables</th><th>Threshold (advanced risk)</th></tr>
          </thead>
          <tbody>
            <tr><td><strong>FIB‑4</strong></td><td>Age, AST, ALT, Platelets</td><td>&gt; <strong>2.67</strong></td></tr>
            <tr><td><strong>NFS</strong></td><td>Age, BMI, Glucose, Platelets, Albumin, AST/ALT</td><td>&gt; <strong>−1.455</strong> (intermediate/high)</td></tr>
            <tr><td><strong>ELF</strong></td><td>HA, PIIINP, TIMP‑1</td><td>≥ <strong>10.51</strong></td></tr>
          </tbody>
        </table>
        <div class="divider"></div>
        <div class="callout" role="note">
          <strong>If low risk</strong> ➜ manage in primary care. <strong>If high / indeterminate / discordant</strong> ➜ <a href="#refer">refer to hepatology</a>.
        </div>
      </section>

      <section class="card" id="manage" aria-labelledby="manage-h2">
        <h2 id="manage-h2">4) Management in Primary Care (if low fibrosis risk)</h2>
        <h3>Lifestyle – cornerstone</h3>
        <ul class="list">
          <li>Weight loss <strong>5–10%</strong> over ~6 months (≈ <strong>600 kcal/day deficit</strong>).</li>
          <li><strong>Mediterranean diet</strong>; prefer water; avoid sugar‑sweetened drinks.</li>
          <li>Physical activity: <strong>150–200 min/week</strong> moderate intensity in 3–5 sessions; combine aerobic + resistance.</li>
        </ul>
        <h3>Risk reduction &amp; pharmacology</h3>
        <ul class="list">
          <li>Keep alcohol within national limits.</li>
          <li>Optimise hypertension, diabetes, lipids. <strong>Statins are safe</strong> and may improve steatosis/inflammation/fibrosis.</li>
          <li>No licensed drugs in primary care for NAFLD. <em>Pioglitazone</em> and <em>Vitamin E</em> for NASH are specialist‑initiated (off‑label; discuss weight gain, bladder cancer risk, osteoporosis in women).</li>
        </ul>
        <div class="tags" aria-label="patient resources">
          <span class="tag">Patient info: British Liver Trust</span>
          <span class="tag">NICE patient leaflet</span>
        </div>
        <div class="alert" style="margin-top:12px">
          <strong>Clinical pearl:</strong> Cardiovascular disease is the leading cause of death in NAFLD—address cardio‑metabolic risk every visit.
        </div>
      </section>

      <section class="card" id="refer" aria-labelledby="refer-h2">
        <h2 id="refer-h2">5) When to Refer to Hepatology</h2>
        <ul class="list">
          <li>High risk for advanced fibrosis by FIB‑4/NFS/ELF.</li>
          <li>Signs of advanced liver disease on examination.</li>
          <li>Diagnostic uncertainty.</li>
        </ul>
      </section>

      <section class="card" id="specialist" aria-labelledby="specialist-h2">
        <h2 id="specialist-h2">6) Specialist Investigations &amp; Management</h2>
        <ul class="list">
          <li><strong>Transient elastography (FibroScan)</strong> for stiffness/fibrosis.</li>
          <li><strong>Liver biopsy</strong> if needed (confirm NASH/cirrhosis; discordant tests).</li>
          <li>Therapies (specialist): pioglitazone, Vitamin E; emerging agents (e.g., obeticholic acid). Consider <strong>bariatric surgery</strong> when appropriate.</li>
          <li><strong>HCC surveillance</strong> for advanced fibrosis/cirrhosis; transplant assessment for decompensation.</li>
        </ul>
      </section>

      <section class="card" id="followup" aria-labelledby="followup-h2">
        <h2 id="followup-h2">7) Follow‑Up in Primary Care (if low risk)</h2>
        <ul class="list">
          <li><strong>Annual review</strong>: BMI/weight, BP, exam for advanced signs.</li>
          <li>Labs: HbA1c, lipids, U&amp;E; manage abnormalities.</li>
          <li>Reassess <strong>CVD risk each year</strong>.</li>
          <li>Reassess <strong>fibrosis every 3 years</strong> (FIB‑4/NFS/ELF). Escalate to hepatology if risk increases.</li>
        </ul>
      </section>
    </main>

    <footer class="wrap" style="margin-top:18px; padding:0">
      <p class="hint">Source: Condensed from NICE CKS (Non‑alcoholic fatty liver disease, last revised Oct 2023) for rapid point‑of‑care use. This single‑page view is informational and does not replace clinical judgment.</p>
    </footer>
  </div>
</body>
</html>
